All In Biotech

NDA 215904 · Immedica Pharma

Ztalmy

Ganaxolone · Oral · Neuroactive Steroid Gamma-Aminobutyric Acid A Receptor Positive Modulator

NovelPriority reviewOrphan

CDER novel approval, Mar 18, 2022: To treat seizures in cyclin-dependent kinase-like 5 deficiency disorder

Last checked: Nov 19, 2026Latest source record: Oct 16, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2022

Mar 18, 2022

Approved uses

2

Original approval plus efficacy supplements

Registered trials

25

8 Phase 3, 0 recruiting

FAERS reports

670

350 serious, 16 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Sep 4, 2026.

ZTALMY is indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ZTALMY is a neuroactive steroid gamma-aminobutyric acid (GABA) A receptor positive modulator indicated for the treatment of seizures associated with cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) in patients 2 years of age and older. ( 1 )

Mechanism: The precise mechanism by which ganaxolone exerts its therapeutic effects in the treatment of seizures associated with CDD is unknown, but its anticonvulsant effects are thought to result from positive allosteric modulation of the gamma-aminobutyric acid type A (GABA A ) receptor in the CNS.

Therapeutic areas: Neurology · Rare and genetic disease

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Oct 16, 2025 Supplement 11 · Efficacy OrphanLetterLabel
  • Mar 18, 2022 Original approval · Type 1 - New Molecular Entity · priority review NovelOrphanLetterLabelReview
1 products under this application
  • ZTALMY · GANAXOLONE 50MG/ML · SUSPENSION, ORAL · Prescription · TE TBD

Clinical trials

Interventional ClinicalTrials.gov studies with "Ganaxolone" as an intervention, any sponsor and status, largest first.

All 25 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • seizure204
  • product dose omission issue101
  • drug ineffective88
  • somnolence58
  • change in seizure presentation43
  • pneumonia31
  • off label use28
  • vomiting24
  • fatigue15
  • illness15
  • weight decreased15
  • pyrexia12

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20212
202224
2023109
2024197
2025279
202659

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Ztalmy (Ganaxolone)

2024 spending

$2.0M

Beneficiaries

12

101 claims

Per beneficiary

$162,989

$24.32 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$952,925
2024$1,955,865

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 20 on PubMed

Sponsor: Immedica Pharma

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.